The global paresthesia treatment industry was valued at US$ 5.4 billion in 2023 and is projected to grow at a CAGR of 3.7% ...

NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the ...

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...

Medical Device Manufacturers Are Playing a Critical Role in Addressing the Evolving Needs of Patients in the Esophageal Motility Disorder ...

A bipartisan Senate bill dubbed the “Skinny Label, Big Savings Act” was introduced in January. The bill would expand the scope of protection ...

Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version ...

The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...

Federal Circuit says only patents claiming the active ingredient of a drug are eligible for listing | Injunction against Teva ...

Teva Pharmaceutical Industries Ltd. failed to convince the Federal Circuit to reconsider a December ruling that five patents ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Jefferies backs Lupin, Zydus, and Biocon amid shifting US pharma market shares. Discover why these stocks are set to shine.